Drug profile · INN
levamlodipine maleate
CONJUPRI
levamlodipine maleate (CONJUPRI) is a voltage-gated l-type calcium channel blocker. Route of administration: oral. Current US regulatory status: approved.
Drug details — levamlodipine maleate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
levamlodipine maleate (CONJUPRI) is a voltage-gated l-type calcium channel blocker. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Voltage-gated L-type calcium channel blocker
Primary target: Voltage-gated L-type calcium channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is levamlodipine maleate?
levamlodipine maleate (CONJUPRI) is a voltage-gated l-type calcium channel blocker. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for levamlodipine maleate?
CONJUPRI is a marketed brand name for levamlodipine maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of levamlodipine maleate?
levamlodipine maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.